Johnson & Johnson News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

10.12.24	J&J : CARVYKTI Shows Higher MRD Negativity Rates Vs. Standard Therapies In Phase 3 Study (RTTNews)
09.12.24	J&J : TECVAYLI Shows Promise As Frontline Therapy For Newly Diagnosed Multiple Myeloma (RTTNews)
09.12.24	J&J : DARZALEX FASPRO Regimens Improve MRD Negativity, Survival In Newly Diagnosed Multiple Myeloma (RTTNews)
02.12.24	Johnson & Johnson Files SBLAs In Pediatric Indications For TREMFYA - Quick Facts (RTTNews)
22.11.24	Johnson & Johnson Submits SBLA Seeking Approval Of TREMFYA In Ulcerative Colitis (RTTNews)
22.11.24	J&J : Canada Approves CARVYKTI For Relapsed Or Refractory Multiple Myeloma After 1-3 Prior Therapies (RTTNews)
18.11.24	CHMP Recommends Approval Of Lazcluze + Rybrevant In EU For EGFR-mutated Advanced NSCLC (RTTNews)
14.11.24	JNJ's Phase 2 Study Of Nipocalimab Shows Improvement In Disease Activity In Sjögren's Disease (RTTNews)
08.11.24	Johnson & Johnson Seeks Approval Of Darzalex Faspro In US, Darzalex In EU For Myeloma Treatment (RTTNews)
28.10.24	J&J Reports Positive Results From GRAVITI Study Of Tremfya In SC Induction And Maintenance Therapy (RTTNews)
25.10.24	J&J Phase 3b SPECTREM Study Of Tremfya In Low Body Surface Area Plaque Psoriasis Meets Primary Goal (RTTNews)
15.10.24	Johnson & Johnson Cuts FY24 Earnings View, Lifts Sales Forecast - Update (RTTNews)
15.10.24	Johnson & Johnson Q3 Profit Decreases, But Beats Estimates (RTTNews)
10.10.24	J&J Says TREMFYA Showed Strong Results In Biologic-Naive & Refractory Patients With CD And UC (RTTNews)
10.10.24	J&J Submits For EMA Approval For DARZALEX SC Quadruplet Regimen In Newly Diagnosed Multiple Myeloma (RTTNews)
09.10.24	Johnson & Johnson Buys Privately-held V-Wave; Sees In-process R&D Charge Of Around $600 Mln In Q4 (RTTNews)
04.10.24	JNJ To Terminate Phase 2 Field Study Of Mosnodenvir For Prevention Of Dengue Virus (RTTNews)
02.10.24	JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer (RTTNews)
30.09.24	Johnson & Johnson Expands Roll-out Of TECNIS Odyssey IOL - Quick Facts (RTTNews)
28.09.24	J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD Negativity In Newly Diagnosed Multiple Myeloma (RTTNews)
28.09.24	J&J : Phase 3 Trial Results Show CARVYKTI Extends Overall Survival In Relapsed Multiple Myeloma (RTTNews)
27.09.24	Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma (RTTNews)
27.09.24	Johnson & Johnson Reports New Data From Phase 1b TRIMM-2 Study (RTTNews)
27.09.24	J&J Reports Data From Investigational Phase 1b RedirecTT-1 Study - Quick Facts (RTTNews)
21.09.24	J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims (RTTNews)
20.09.24	Janssen-Cilag Reports CHMP Recommendation For Daratumumab - Quick Facts (RTTNews)
20.09.24	FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy (RTTNews)
16.09.24	Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study (RTTNews)
15.09.24	J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer (RTTNews)
14.09.24	J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer (RTTNews)
14.09.24	J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial (RTTNews)
12.09.24	Janssen-Cilag Announces First EMA Submission For Nipocalimab - Quick Facts (RTTNews)
12.09.24	J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults (RTTNews)
11.09.24	J&J's Dexamethasone Regimen Reduces Infusion Reactions In EGFR-Mutated NSCLC Patients On RYBREVANT (RTTNews)
09.09.24	J&J : Phase 3 Data Show RYBREVANT + LAZCLUZE Outperforms Osimertinib In Non-small Cell Lung Cancer (RTTNews)
01.09.24	Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies (RTTNews)
29.08.24	J&J Files For FDA Approval Of Nipocalimab To Treat Generalized Myasthenia Gravis (RTTNews)
25.08.24	Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug (RTTNews)
23.08.24	Janssen-Cilag's Balversa Gets EC Approval For Metastatic Urothelial Carcinoma (RTTNews)
20.08.24	Johnson & Johnson To Acquire V-Wave For Initial Payment Of $600 Mln (RTTNews)
20.08.24	Johnson & Johnson's Chemotherapy-free Lung Cancer Treatment Rybrevant Plus Lazcluze Gets FDA Nod (RTTNews)
31.07.24	Johnson & Johnson : FDA Approves Darzalex Faspro Combination For Multiple Myeloma (RTTNews)
26.07.24	J&J: CHMP Recommends RYBREVANT With Chemo To Treat Advanced EGFR-mutated NSCLC (RTTNews)
26.07.24	Johnson & Johnson's Yuvanci Gets Positive CHMP Opinion In Europe For Pulmonary Arterial Hypertension (RTTNews)
22.07.24	Johnson & Johnson Seeks FDA Approval For SPRAVATO Nasal Spray For Treatment-Resistant Depression (RTTNews)
17.07.24	Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast (RTTNews)
17.07.24	Johnson & Johnson Q2 Profit Decreases, But Beats Estimates (RTTNews)
17.07.24	ORIC Enters Into Clinical Trial Collaboration And Supply Agreements With Bayer and J&J; Stock Up (RTTNews)
03.07.24	Johnson & Johnson Announces Health Canada NOC For RYBREVANT Combination - Quick Facts (RTTNews)
02.07.24	J&J Reports Positive Data From Phase 3 CARTITUDE-4 Study Of Carvykti In Multiple Myeloma (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

SPI-Handel aktuell: SPI zum Handelsende leichter

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter